Specimen Collection Manual and Test Catalog
C-KIT MUTATIONS WITH REFLEX TO PDGFRA MUTATIONS FOR GIST
Geisinger Epic Procedure Code: LAB1239 Geisinger Epic ID: 52881Formalin-fixed, paraffin-embedded tissue block (preferred) or whole blood or bone marrow
Formalin-fixed, paraffin-embedded tissue block (preferred) OR 6 mL whole blood; minimum 4 mL OR 3 mL bone marrow; minimum 1 mL
After collection of the sample, draw date and time, as well as sample type, must be written on the tube and included as requested information.
Tissue block: Room temperature.
Whole blood or bone marrow: Refrigerated (cold packs). Do not freeze whole blood or bone marrow.
Tissue block: Room temperature: Indefinitely. Refrigerated: Indefinitely. Frozen: Unacceptable.
Whole blood or bone marrow: Room temperature: 7 days. Refrigerated: 14 days. Frozen: Unacceptable.
Gross hemolysis • Clotted or frozen whole blood • Clotted or frozen bone marrow
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
c-KIT Mutation Analysis, Cell-based; PDGFRA Mutation Analysis. If C-KIT Mutation, Cell-based result is Not detected, PDGFRA Mutation Analysis will be performed at an additional charge (CPT code(s): 81314).
Sequencing
Quest test code 16237, cKIT PDGFRA
Eighty percent of patients with gastrointestinal stromal tumor (GIST) have a C-KIT mutation in exon 9, 11, 13, or 17. The presence of a mutation usually predicts poor survival. Patients with C-KIT mutations other than D816V are likely to respond to imatinib (Gleevec) therapy. Mutations in the PDGFRA gene are found in about 7% of gastrointestinal stromal tumors (GISTs), especially in KIT wild type GISTs. PDGFRA mutations also have been described in synovial sarcomas (SSs) and malignant peripheral nerve sheath tumors (MPNST). GISTs with PDGFRA mutations (except D842V) are likely to respond to imatinib.